SynthesisEvidence-based dentistry2025
Efficacy of alternative agents to Carnoy's solution in the prevention of recurrence in odontogenic keratocyst: a systematic review and meta-analysis.
Synthesis in Evidence-based dentistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of a Symphyseal Multilocular Odontogenic Keratocyst.Journal of medical cases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimOdontogenic keratocyst (OKC) is aggressive cyst with high recurrence rates, traditionally treated using Carnoy's solution (CS) as an adjunct to surgical enucleation. However, the toxicity and potential complications of CS, including neurotoxicity and tissue damage, necessitate the exploration of safer alternatives. The aim of systematic review was to evaluate potential alternatives to CS for preventing recurrence and minimizing postoperative complications in OKC.
methodsStudies were searched and retrieved from PubMed, Scopus, and Web of Science using relevant keywords. Inclusion criteria focused on studies evaluating alternatives to CS for OKC treatment, while reviews, case reports, and non-clinical studies were excluded. Quality assessment was performed using the Newcastle-Ottawa Scale and Cochrane Risk of Bias 2 Tool. Data extraction included study design, intervention, recurrence rates, and complications. Findings were summarized descriptively. Meta-analysis (random-effect model) was performed for recurrence in OKC.
resultsSix studies met the inclusion criteria after examining 280 studies. These studies examined recurrence and post-operative complications in CS, modified CS (MCS), and 5- Fluorouracil (5-FU) treated OKC cases. The recurrence events were 15/153 with CS and 37/200 with MCS; however, no recurrence was recorded for 5-FU. Paresthesia was seen in 17/74 of OKC-treated CS/MCS cases and 12/72 of OKC-treated 5-FU cases after surgery. The random-effects model estimated a pooled risk ratio of 0.13 (95% CI: 0.02 to 0.68, p = 0.015), suggesting that the 5-FU treated OKC patients was significantly less likely to experience recurrence than the CS/MCS treated OKC patients.
conclusion5-FU is found to be a better alternative to CS or MCS in terms of recurrence and postoperative complications in OKC. While 5-FU and/or CS remain effective, its side effects highlight the need for safer, equally effective alternatives. Future research should focus on long-term outcomes and the efficacy of novel treatments, including herbal therapies.
Indexed as
Identifiers
40269316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.